Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 2.6/5

Exact Sciences (EXAS US)

34
Analysis
Health Care • United States
Exact Sciences Corp., is focused on developing and commercializing a non-invasive molecular screening test for the early detection and prevention of colorectal cancer. The Company's test is a stool-based DNA test that identifies both pre-cancer and cancer by detecting genetic mutations in colorectal cancer cells.
more
bullish•Exact Sciences
•24 Aug 2025 09:00

Exact Sciences Reinforces Its Market Edge With Strategic Alliances & Profit Growth!

Exact Sciences Corporation reported its financial results for the second quarter of 2025. The company delivered strong performance metrics and...

Logo
201 Views
Share
bullish•Circle Internet Group
•07 Oct 2025 21:53

Downgrading Financials to Underweight; Growth Themes Galore; Health Care Breaking Out

Downgrading Financials $XLF to Underweight; Growth Themes Galore: quantum, nuclear, hydrogen, space, robotics, drones, data centers, solar,...

Logo
189 Views
Share
bullish•Exact Sciences
•24 May 2025 10:00

Exact Sciences: Launch of Cologuard Plus to Redefine Colorectal Cancer Screening Paradigm!

Exact Sciences' first quarter 2025 financial results reflect a blend of robust revenue growth, strategic commercial execution, and significant...

Logo
457 Views
Share
bullish•Exact Sciences
•06 Mar 2025 06:00

Exact Sciences Corporation: Is The Oncology Product Pipeline Development to Capture A Lion’s Share of the Market?

Exact Sciences recently reported its fourth-quarter 2024 financial results, showcasing a mix of both positive momentum and certain challenges. For...

Logo
194 Views
Share
bullish•Exact Sciences
•10 Dec 2024 05:00

Exact Sciences: Expansion of the Customer Base & Provider Engagement As A Vital Tool For Growth! - Major Drivers

Exact Sciences Corporation's third-quarter 2024 earnings highlighted both achievements and challenges faced by the company. The overall financial...

Logo
217 Views
Share
x